Effect of Lacidipine on Blood Pressure and Endothelial Function in Mild-to-Moderate Essential Hypertension Patients With Diabetes in Korea.
10.4070/kcj.2010.40.12.632
- Author:
Dae Hee KIM
1
;
Il Young OH
;
Hae Young LEE
;
Yong Jin KIM
;
Hyo Soo KIM
;
Cheol Ho KIM
;
Byung Hee OH
;
Kwon Sam KIM
;
Doo Il KIM
;
Young Dae KIM
;
Kyu Hyung RYU
;
Si Hoon PARK
;
Sang Hong BAEK
;
Dong Gu SHIN
;
Wan Joo SHIM
;
Tae Hoon AHN
;
Seok Kyu OH
;
Seung Hwan LEE
;
Sung Yun LEE
;
Myung Ho JEONG
;
Wook Sung CHUNG
;
Jun Young JEONG
;
So Yeon CHOI
;
Si Wan CHOI
;
Min Su HYON
Author Information
1. Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea. ohbhmed@snu.ac.kr
- Publication Type:Multicenter Study ; Original Article
- Keywords:
Lacidipine;
Diabetes mellitus;
Hypertension;
Endothelium
- MeSH:
Biomarkers;
Blood Pressure;
C-Reactive Protein;
Diabetes Mellitus;
Diabetes Mellitus, Type 2;
Dihydropyridines;
Endothelium;
Humans;
Hypertension;
Korea;
Matrix Metalloproteinase 9;
Monocytes;
Plasminogen Activators;
Prospective Studies;
Vasodilation
- From:Korean Circulation Journal
2010;40(12):632-638
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate the efficacy of lacidipine in reducing blood pressure (BP) and to determine its effect on endothelial function in mild-to-moderate hypertensive patients with type 2 diabetes mellitus (DM). SUBJECTS AND METHODS: This was a prospective, multicenter, open-label, single-arm study, enrolling 290 patients with mild-to-moderate hypertension and type 2 DM. Patients were initially treated with 2 mg lacidipine orally once daily for 4 weeks, which was then increased as necessary every 4 weeks to a maximal dose of 6 mg daily. The primary endpoint was the mean change in systolic blood pressure (SBP) from baseline after 12 weeks of treatment. Secondary endpoints included mean changes in diastolic blood pressure (DBP), flow-mediated vasodilatation (FMD), and serum concentrations of biochemical markers such as high-sensitivity C-reactive protein (hs-CRP), monocyte chemo-attractant protein-1 (MCP-1), matrix metalloproteinase-9 (MMP-9), and plasminogen activator inhibitor-1 (PAI-1). RESULTS: Lacidipine treatment significantly reduced SBP by -13.4+/-13.0 mmHg (p<0.001) and DBP by -6.2+/-9.3 mmHg (p<0.001). Lacidipine treatment did not improve endothelial-dependent vasodilatation, despite significantly improved nitroglycerin-induced, endothelial-independent vasodilatation. MCP-1 levels significantly decreased from 283.66+/-110.08 pg/mL to 257.83+/-100.23 pg/mL (p<0.001); whereas there were no significant changes in the levels of hs-CRP, MMP-9, or PAI-1. CONCLUSION: Twelve weeks of treatment with lacidipine was effective and well tolerated in mild-to-moderate hypertensive patients with type 2 DM. In spite of inducing a significant reduction in MCP-1 levels, lacidipine did not improve endothelial function.
